ST. JOSEPH, Mich., March 8 /PRNewswire/ -- GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox(TM) partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.
ToxHunter includes a unique, detailed ontology of compound-induced pathological observations covering 7 target organs in the initial release, as well as a comprehensive, manually-curated knowledgebase of gene, protein, metabolite, and chemical associations to pathology terms that is searchable by pathology, toxicant, or gene, protein & metabolite biomarkers. ToxHunter also enables new experimental analysis and visualization tools such as an exclusive enrichment module for identifying specific gene-pathology associations, and a suite of new toxicity-focused pathway maps and QSAR models.
“It is very important to GeneGo and our end users that we build these tools and content in collaboration with partners as they know exactly what they need and what is currently missing in the marketplace,” said Julie Bryant, VP Business Development. “We truly believe we have delivered important productivity tools to the tox field based on the extremely positive feedback we have already received from ToxHunter demonstrations.”
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 6.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
ToxHunter(TM), MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
